Trial Profile
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs DSP-0337 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 18 Nov 2020 Status changed from recruiting to discontinued due to alternate development strategy.
- 20 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020.
- 20 Jul 2020 Planned primary completion date changed from 1 May 2020 to 1 Jul 2020.